{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:39:54Z","timestamp":1792813194691,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA015396"],"award-info":[{"award-number":["P01 CA015396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P01 CA225618"],"award-info":[{"award-number":["P01 CA225618"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2022.100990","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T21:59:27Z","timestamp":1657749567000},"page":"100990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The next horizon now that everyone has a donor: Precision allogeneic transplantation"],"prefix":"10.1016","volume":"62","author":[{"given":"Richard J.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2022.100990_bb0005","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0010","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0015","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Martinez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0025","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0030","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-016-0248-3","article-title":"Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT","volume":"9","author":"Rubio","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0040","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0050","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-Sponsored Multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2014.10.002","article-title":"8\/8 and 10\/10 high-resolution match rate for the be the match unrelated donor registry","volume":"21","author":"Dehn","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0070","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/leu.2012.210","article-title":"Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings","volume":"27","author":"Kroger","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100990_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bmt.1705388","article-title":"Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?","volume":"38","author":"Mehta","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0080","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.leukres.2015.05.003","article-title":"Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome","volume":"39","author":"Bastida","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100990_bb0085","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0090","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/01621459.1999.10473858","article-title":"Causal effects in nonexperimental studies: reevaluating the evaluation of training programs","volume":"94","author":"Dehejia","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.blre.2022.100990_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal"},{"key":"10.1016\/j.blre.2022.100990_bb0100","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1037\/a0036515","article-title":"Examining moderation analyses in propensity score methods: application to depression and substance use","volume":"82","author":"Green","year":"2014","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.blre.2022.100990_bb0105","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.blre.2022.100990_bb0110","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1093\/cid\/ciaa169","article-title":"Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections","volume":"71","author":"Amoah","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2022.100990_bb0115","series-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","author":"Ambinder","year":"2022"},{"key":"10.1016\/j.blre.2022.100990_bb0120","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/bloodadvances.2018025726","article-title":"Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0125","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0130","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30022-X","volume":"5","author":"Fasslrinner","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2022.100990_bb0140","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0150","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/tan.12090","article-title":"Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies","volume":"81","author":"Warren","year":"2013","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.blre.2022.100990_bb0160","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0165","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/bloodadvances.2021006831","article-title":"Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT","volume":"6","author":"Kinoshita","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0170","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2021014648","article-title":"Donor-derived multiple leukemia antigen\u2013specific T-cell therapy to prevent relapse after transplant in patients with ALL","volume":"139","author":"Naik","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0175","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2018.12.767","article-title":"Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide","volume":"25","author":"McCurdy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0180","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood.V77.7.1423.1423","article-title":"Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia","volume":"77","author":"Bacigalupo","year":"1991","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0185","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V95.5.1572.005k12_1572_1579","article-title":"Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial","volume":"95","author":"Locatelli","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0190","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3324\/haematol.2009.013920","article-title":"Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia","volume":"95","author":"Craddock","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2022.100990_bb0195","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1002\/sctm.20-0481","article-title":"Optimizing allogeneic grafts in hematopoietic stem cell transplantation","volume":"Suppl 2","author":"Xu","year":"2021","journal-title":"Stem Cells Transl Med."},{"key":"10.1016\/j.blre.2022.100990_bb0200","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature."},{"issue":"12","key":"10.1016\/j.blre.2022.100990_bb0205","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.exphem.2016.08.010","article-title":"Translating leukemia stem cells into the clinical setting: harmonizing the heterogeneity","volume":"44","author":"Yanagisawa","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2022.100990_bb0210","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","article-title":"FLT3\/ITD AML and the law of unintended consequences","volume":"117","author":"Levis","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/imt.10.20","article-title":"Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects","volume":"2","author":"Bouchlaka","year":"2010","journal-title":"Immunotherapy."},{"key":"10.1016\/j.blre.2022.100990_bb0220","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.aaf2288","article-title":"Targeting of cancer neoantigens with donor-derived T cell receptor repertoires","volume":"352","author":"Str\u00f8nen","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.blre.2022.100990_bb0225","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.bbmt.2019.09.022","article-title":"Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for Philadelphia chromosome-positive acute lymphoblast leukemia: a systematic review","volume":"26","author":"Warraich","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0230","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/bloodadvances.2020002945","article-title":"Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide","volume":"4","author":"Webster","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.630429","article-title":"TKI maintenance after stem-cell transplantation for FLT3-ITD positive acute myeloid leukemia: a systematic review and meta-analysis","volume":"12","author":"Gagelmann","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2022.100990_bb0240","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0245","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2021-147962","article-title":"Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)","volume":"138","author":"Mishra","year":"2021","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100990_bb0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clml.2021.09.022","article-title":"Nonmyeloablative allogeneic transplantation with post-transplant cyclophosphamide for acute myeloid leukemia with IDH mutations: a single center experience","volume":"22","author":"Ambinder","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2022.100990_bb0255","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0260","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2019-128255","article-title":"A phase IB study of blinatumomab (blina) in patients with B cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (NHL) as post-allogeneic blood or marrow transplant (Allo-BMT) remission maintenance","volume":"134","author":"Webster","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0265","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0270","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2013.10.024","article-title":"Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201","volume":"20","author":"Switzer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0275","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2016.2520","article-title":"Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial","volume":"2","author":"Lee","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2022.100990_bb0280","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2011-05-354001","article-title":"Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia","volume":"118","author":"Eapen","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0285","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.exphem.2016.04.005","article-title":"Peripheral blood stem cell versus bone marrow transplantation: a perspective from the acute leukemia working Party of the European Society for blood and marrow transplantation","volume":"44","author":"Byrne","year":"2016","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.blre.2022.100990_bb0290","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Posttransplantation cyclophosphamide-based graft versus host disease prophylaxis with non-myeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.blre.2022.100990_bb0295","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100990_bb0300","doi-asserted-by":"crossref","DOI":"10.1179\/102453312X13336169155097","article-title":"Allogeneic transplantation for aplastic anemia","volume":"17","author":"Eapen","year":"2012","journal-title":"Hematology."},{"key":"10.1016\/j.blre.2022.100990_bb0305","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100990_bb0310","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in Cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2022.100990_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30117-X","article-title":"Haemopoietic cell transplantation in patients living with HIV","volume":"7","author":"Ambinder","year":"2020","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.blre.2022.100990_bb0320","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with post-transplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100990_bb0325","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbmt.2019.12.765","article-title":"Donor KIR2DS1-mediated decreased relapse and improved survival depending on remission status at HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"26","author":"Ido","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0330","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ejh.13740","article-title":"The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands","volume":"108","author":"van Gorkom","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2022.100990_bb0335","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2022.100990_bb0340","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0345","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide","volume":"4","author":"DeZern","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.100990_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2022.100990_bb0355","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative","volume":"25","author":"de la Fuente","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.100990_bb0360","first-page":"1238","article-title":"HLA class I antigen expression in human solid tumors","volume":"32","author":"Klein","year":"1996","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.blre.2022.100990_bb0365","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.3390\/ijms22136741","article-title":"MHC class I deficiency in solid tumors and therapeutic strategies to overcome it","volume":"22","author":"Shklovskaya","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2022.100990_bb0370","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1586\/era.11.12","article-title":"Allogeneic stem cell transplantation for renal cell carcinoma","volume":"11","author":"Bregni","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.blre.2022.100990_bb0375","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1517\/14712598.2011.566855","article-title":"Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after","volume":"11","author":"Tykodi","year":"2011","journal-title":"Expert Opin Biol Ther"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:33:28Z","timestamp":1759437208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":75,"alternative-id":["S0268960X22000649"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100990","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The next horizon now that everyone has a donor: Precision allogeneic transplantation","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100990"}}